Arcutis Biotherapeutics, Inc. (ARQT)
NMS · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
No filing content received for Arcutis (ARQT) ARS summary
I am ready to put my full expertise to work! I understand the strict rules and the need to create a deeply comprehensive, educational summary. However, the document content itself appears to be missing. I received the metadata (Company: Arcutis Biotherapeutics, Inc. and Form: ARS) but the actual PD
ARQT annual proxy details director votes and executive compensation review
# 📰 What This Document Is ✉️ This filing is a **Definitive Proxy Statement (DEF 14A)**. In simple terms, this document is a comprehensive "instruction manual" for the company’s annual meeting. It tells stockholders everything they need to know—from who is running the company to how they are paid—an
SEC filings
All filings →Insider trades
All insider trades →Arcutis Biotherapeutics, Inc. has no reported insider trades in the last 90 days.